TY - JOUR
T1 - Synthesis, estrogen receptor binding, and tissue distribution of [18F]fluorodoisynolic acids
AU - Scribner, Andrew W.
AU - Jonson, Stephanie D.
AU - Welch, Michael J.
AU - Katzenellenbogen, John A.
N1 - Funding Information:
We are grateful for support of this research through grunts from theN ational Institutes of Health (PHS 5R37DK15556 to J.A.K.), the Department of Energy (DE FG02-84ER60218 to M.J.W.), and the Department of Defense (DAMDI 7-94-J-4029 to S.D.].). We are grateftuo lK uthryn E. Carlson, Elizabeth L. C. Sherman, and Lynne Jones for their technical assistance.
PY - 1997/4
Y1 - 1997/4
N2 - Doisynolic acids, D-ring seco-steroids derived from alkaline fusion of estrones, are hormonal curiosities: Their binding affinity for the estrogen receptor is low (ca. 1-2% that of estradiol), but their in vivo potency is high and they have a long duration of action. To study the in vivo behavior of the doisynolic acids, we prepared fluorine-substituted analogs of both trans-doisynolic acid (with the natural 14α-hydrogen configuration, trans- FDA) and the more active cis-doisynolic acid (with the unnatural 14β- hydrogen configuration, cis-FDA) from estrone and 14β-estrone, respectively. Modification of the D-ring haloform cleavage approach of Meyers allowed us to introduce fluorine (or fluorine-18) on the carbon atom derived from C-16 in the estrones. Fluorine substitution had little effect on the estrogen receptor binding affinity of the doisynolic acids. Tissue distribution of the fluorodoisynolic acids (trans-[18F]FDA and cis-[18F]FDA) was unusual and very different from that of typical, high-affinity ligands for the estrogen receptor. At 1-3 h in immature female rats, trans-[18F]FDA shows low and rather nonselective uptake in the principal estrogen target tissue (uterus) and slow clearance. By contrast, cis-[18F]FDA shows high uptake in nearly all tissues, with significant uterine uptake that continues to increase over the 1-6-h period. The uterine uptake of this isomer was blocked at the later times by a sufficiently high dose of unlabeled cis-FDA. After administration of the trans-[18F]FDA, a more polar metabolite slowly accumulates in the blood. The cis-[18F]FDA, however, showed no apparent metabolism, with 84% of the blood activity at 5 h assigned as the unmetabolized radioligand. After 5 h, only limited clearance from blood, liver, and kidneys has occurred. No metabolite from this isomer accumulates in the uterus. Although fluorodoisynolic acids will not be useful breast-tumor imaging agents, their behavior was found to be interesting as it deviates from that of other F-18 estrogens. Further long-term studies of cis-doisynolic acid, labeled with tritium, may be needed to explicate fully its unusual distribution properties and high in vivo activity.
AB - Doisynolic acids, D-ring seco-steroids derived from alkaline fusion of estrones, are hormonal curiosities: Their binding affinity for the estrogen receptor is low (ca. 1-2% that of estradiol), but their in vivo potency is high and they have a long duration of action. To study the in vivo behavior of the doisynolic acids, we prepared fluorine-substituted analogs of both trans-doisynolic acid (with the natural 14α-hydrogen configuration, trans- FDA) and the more active cis-doisynolic acid (with the unnatural 14β- hydrogen configuration, cis-FDA) from estrone and 14β-estrone, respectively. Modification of the D-ring haloform cleavage approach of Meyers allowed us to introduce fluorine (or fluorine-18) on the carbon atom derived from C-16 in the estrones. Fluorine substitution had little effect on the estrogen receptor binding affinity of the doisynolic acids. Tissue distribution of the fluorodoisynolic acids (trans-[18F]FDA and cis-[18F]FDA) was unusual and very different from that of typical, high-affinity ligands for the estrogen receptor. At 1-3 h in immature female rats, trans-[18F]FDA shows low and rather nonselective uptake in the principal estrogen target tissue (uterus) and slow clearance. By contrast, cis-[18F]FDA shows high uptake in nearly all tissues, with significant uterine uptake that continues to increase over the 1-6-h period. The uterine uptake of this isomer was blocked at the later times by a sufficiently high dose of unlabeled cis-FDA. After administration of the trans-[18F]FDA, a more polar metabolite slowly accumulates in the blood. The cis-[18F]FDA, however, showed no apparent metabolism, with 84% of the blood activity at 5 h assigned as the unmetabolized radioligand. After 5 h, only limited clearance from blood, liver, and kidneys has occurred. No metabolite from this isomer accumulates in the uterus. Although fluorodoisynolic acids will not be useful breast-tumor imaging agents, their behavior was found to be interesting as it deviates from that of other F-18 estrogens. Further long-term studies of cis-doisynolic acid, labeled with tritium, may be needed to explicate fully its unusual distribution properties and high in vivo activity.
KW - Doisynolic acid
KW - Estrogen receptor
KW - Estrogens
KW - Fluorine-18
KW - Uterus
UR - http://www.scopus.com/inward/record.url?scp=0030741696&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0030741696&partnerID=8YFLogxK
U2 - 10.1016/S0969-8051(97)00058-9
DO - 10.1016/S0969-8051(97)00058-9
M3 - Article
C2 - 9228655
AN - SCOPUS:0030741696
SN - 0969-8051
VL - 24
SP - 209
EP - 224
JO - International journal of radiation applications and instrumentation. Part B, Nuclear medicine and biology
JF - International journal of radiation applications and instrumentation. Part B, Nuclear medicine and biology
IS - 3
ER -